Torsten Dahlen
Overview
Explore the profile of Torsten Dahlen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
133
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen E, Dahlen T, Stenke L, Bjorkholm M, Hao S, Dickman P, et al.
Eur J Haematol
. 2024 Nov;
114(2):334-342.
PMID: 39501755
The introduction of tyrosine kinase inhibitors has considerably improved the life expectancy (LE) for patients with chronic myeloid leukemia (CML). Evaluating health-related quality of life within the treatment pathway remains...
2.
Dahlen T, Zhao J, Busch M, Edgren G
Lancet Digit Health
. 2024 Jan;
6(2):e105-e113.
PMID: 38278613
Background: Identification and prevention of transfusion-transmitted disease is essential for blood transfusion safety. However, current surveillance systems are largely driven by reports of sentinel events, which is an approach that...
3.
Zhao J, Rostgaard K, Lauwers E, Dahlen T, Ostrowski S, Erikstrup C, et al.
JAMA
. 2023 Sep;
330(10):941-950.
PMID: 37698562
Importance: Recent reports have suggested that cerebral amyloid angiopathy, a common cause of multiple spontaneous intracerebral hemorrhages (ICHs), may be transmissible through parenteral injection of contaminated cadaveric pituitary hormone in...
4.
The impact of Covid-19 in patients with chronic myeloid leukemia-a nationwide population-based study
Dahlen T, Flygt H, Lubking A, Olsson-Stromberg U, Wennstrom L, Dreimane A, et al.
Leukemia
. 2023 Apr;
37(5):1156-1159.
PMID: 37037908
No abstract available.
5.
Dahlen T, Li H, Nyberg F, Edgren G
J Intern Med
. 2022 Nov;
293(3):398-402.
PMID: 36372955
Background: Several studies have investigated associations between ABO blood group and risk of COVID-19, with inconsistent results. Objective: To study associations between ABO blood group and risk of different stages...
6.
Shahim B, Redfors B, Lindman B, Chen S, Dahlen T, Nazif T, et al.
J Am Heart Assoc
. 2022 Jun;
11(11):e024091.
PMID: 35656983
Background The neutrophil-to-lymphocyte ratio (NLR) as a marker of systemic inflammation has been associated with worse prognosis in several chronic disease states, including heart failure. However, few data exist on...
7.
Dahlen T, Edgren G, Ljungman P, Flygt H, Richter J, Olsson-Stromberg U, et al.
Am J Hematol
. 2022 Jan;
97(4):421-430.
PMID: 35015312
Tyrosine kinase inhibitors (TKIs) have profoundly improved the clinical outcome for patients with chronic myeloid leukemia (CML), but their overall survival is still subnormal and the treatment is associated with...
8.
Dahlen T, Zhao J, Magnusson P, Pawitan Y, Lavrod J, Edgren G
J Intern Med
. 2021 Jul;
291(1):95-100.
PMID: 34288189
Background: The occurrence of misattributed paternity has consequences throughout society with implications ranging from inheritance and royal succession to transplantation. However, its frequency in Sweden is unknown. Objective: To estimate...
9.
Dahlen T, Clements M, Zhao J, Olsson M, Edgren G
Elife
. 2021 Apr;
10.
PMID: 33902814
Background: There are multiple known associations between the ABO and RhD blood groups and disease. No systematic population-based studies elucidating associations between a large number of disease categories and blood...
10.
Flygt H, Sandin F, Dahlen T, Dremaine A, Lubking A, Markevarn B, et al.
Br J Haematol
. 2021 Mar;
193(5):915-921.
PMID: 33782950
Clinical trials show that tyrosine kinase inhibitor (TKI) treatment can be discontinued in selected patients with chronic myeloid leukaemia (CML). Although updated CML guidelines support such procedure in clinical routine,...